• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21894 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cipaglucosidase alfa (Pompe disease) – Addendum to Project A23-79]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somapacitan (growth hormone deficiency, adults) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     NIHR Health Services and Delivery Research programme Conceptual framework on barriers and facilitators to implementing perinatal mental health care and treatment for women: the MATRIx evidence synthesis
2024     NIHR Health Services and Delivery Research programme Factors within the clinical encounter that impact upon risk assessment within child and adolescent mental health services: a rapid realist synthesis
2024     NIHR Public Health Research (PHR) programme Support needs of survivors of violence against women in urban India: a prospective analysis of client records
2024     Health Information and Quality Authority (HIQA) Advances in the development of clinical practice guidance - scoping review
2024     Health Information and Quality Authority (HIQA) Enhanced inactivated influenza vaccines for over 65s: protocol for a health technology assessment
2024     Health Information and Quality Authority (HIQA) Herpes zoster (shingles) vaccination: protocol for a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Health Technology Wales (HTW) Intensive family preservation programmes for families in crisis
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: the experience of people living with neurocognitive disorders in Quebec]
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Belgian Health Care Knowledge Centre (KCE) Use of diagnostic immunohistochemistry and electron microscopy tests in Belgium (Study 2021-01)
2024     Belgian Health Care Knowledge Centre (KCE) Large-scale lung cancer screening (Study 2021-02)
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell counting in the preoperative evaluation of cataract surgery (Study 2023-12)
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine formulations for opioid use disorder
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic drugs for severe asthma
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aging in place
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation for the management of resistant hypertension]
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic and clinical utility of impulse oscillometry for use in patients with difficulty performing spirometry]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post covid and other post infectious diseases]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Adaptive deep brain stimulation in Parkinson's disease]
2023     The Danish Health Technology Council (DHTC) [Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023     HTA Region Stockholm [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on risk of exacerbation of disease in patients with inflammatory bowel disease (IBD)]
2023     The Danish Health Technology Council (DHTC) [High-tech hospital beds for use in intensive and neurological wards]
2023     Center for Drug Evaluation (CDE) [Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023     Ontario Health Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023     Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023     Ontario Health Robotic-assisted partial nephrectomy for kidney cancer
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023     The Regional Health Technology Assessment Centre (HTA-centrum) [Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023     The Regional Health Technology Assessment Centre (HTA-centrum) General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (diffuse large B-cell lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (follicular lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal strategy for subsidizing pneumococcal vaccination in the elderly]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Center for Drug Evaluation (CDE) [Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2023     Agency for Care Effectiveness (ACE) Presbyopia-correcting intraocular lenses for treating patients with cataract
2023     Agency for Care Effectiveness (ACE) Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
2023     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
2023     Agency for Care Effectiveness (ACE) Romosozumab and teriparatide for treating osteoporosis
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talquetamab (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]